FilingReader Intelligence
Chugai to build $500m Tokyo lab, reports steady growth
July 28, 2025 at 07:04 AM UTC•By FilingReader AI
Chugai Pharmaceutical plans to construct a new research building at its Tokyo site with an estimated investment of 80bn yen, scheduled for completion by August 2028.
The company reported second quarter revenue of 578.5bn yen, up 4.6% year-on-year, with operating profit rising 5.8% to 273.3bn yen.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
A decision has been made to construct a new research building (UKX) to strengthen pharmaceutical manufacturing process development capabilities and promote environmental measures towards achieving TOP I 2030.July 24, 2025 at 07:00 AM UTC
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2025)July 24, 2025 at 07:00 AM UTC
Chugai to Construct a New Laboratory Building "UKX" to Strengthen Manufacturing Process Development Capabilities and Advance Environmental InitiativesJuly 24, 2025 at 07:00 AM UTC
Supplementary materials for the consolidated financial results (interim) for the second quarter of the fiscal year ending December 2025 [IFRS]July 24, 2025 at 07:00 AM UTC
Supplementary Materials Consolidated Financial Statements for the six months ended June 30, 2025 (IFRS)July 24, 2025 at 07:00 AM UTC
TSE:4519•Tokyo Stock Exchange
News Alerts
Get instant email alerts when Chugai Pharmaceutical publishes news
Free account required • Unsubscribe anytime